This article provides key insights and suggested best practices for managed care to improve patient care in MPS disorders, which may also be relevant to other rare and ultra-rare conditions.
AMCP signs on to stakeholder letter in support of H.R. 6478 - the Biosimilars Competition Act
We are writing to express our support for the Biosimilars Competition Act of 2018 (H.R. 6478). The undersigned stakeholders share your commitment to promoting a biosimilars market that will help reduce prescription drug costs for patients, payers, and taxpayers. We commend you for introducing this important legislation and look forward to working with you to enact it into law.
Related
As part of a multi-year RWE initiative, AMCP Research Institute partnered with IQVIA, payers, pharmaceutical companies, and others to design payer-focused RWE standards that were published in JMCP in September, 2025.
AMCP’s guidance translates CMS’s expectations for patient centered, evidence informed formulary decisions into practical steps payers can act on today without adding unnecessary burden to P&T workflows.
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
